An Early Phase 1 interventional study of Xenon and Nitrogen gas in Major Depressive Disorder and Bipolar Depression, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Massachusetts General Hospital · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Depressive Disorder, Major by Massachusetts General Hospital — 9 open to participants now, 12 under way, none of them phase 3. Depressive Disorder, Major · Massachusetts General Hospital.
Among the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, this one is the 63rd largest by enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2019, is one of 2 in phase 1, and was the 67th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →9 of the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 25–50
Massachusetts General Hospital · Sites in United States
Ages 18–65 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 5 · Phase 4 15
First in 2001; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 40 across the 77 interventional studies, 70 across the 11 observational. Of the 68 that completed or were terminated, 41 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
6 of the studies in Depressive Disorder, Major by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05767593Massachusetts General HospitalClinical Validation of Samsung Smartwatch | 2026-12-01 |
| NCT07610928Massachusetts General HospitalStress Management and Meditative Movements for Asian Americans With Depression and Physical Symptoms | 2027-03-31 |
| NCT05774665Massachusetts General HospitalSpecialized Pro-resolving Lipid Mediators and Treatment Resistant Depression | 2027-03-31 |
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
| NCT05570812Massachusetts General HospitalNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 88 studies in Depressive Disorder, Major by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.
Major depressive disorder (MDD) occurs in up to 17% of the population, is associated with profound dysfunction and, according to the WHO Global Burden of Disease Study, is estimated to become the second leading cause of disability worldwide by 2020. While antidepressants have proven efficacy, they usually take weeks to work and then only about a third of patients reach remission.
Beyond the traditional monoaminergic approaches, recent advances in understanding the pathophysiology of MDD have focused on the dysregulation of glutamate and associated neuronal glutaminergic associated excitotoxicity. Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants, and has the potential to be a novel antidepressant drug.
Although mania or hypomania are the defining characteristics of bipolar disorder, throughout the course of the illness depressive symptoms are more common than manic symptoms. People with bipolar disorder spend a substantial proportion of time with syndromal or subsyndromal depressive symptoms. The risk of suicide is greatly elevated during depressive episodes. Approximately 17% of people with bipolar I disorder and 24% with bipolar II disorder attempt suicide during the course of their illness. Annually around 0.4% of people with bipolar disorder will die by suicide, which is vastly greater than the international population average of 0.017%.
Pharmacological treatments are commonly used during episodes of mania and bipolar depression. Over time these episodes, particularly depression, tend to become more frequent and as repeated episodes are associated with increased functional impairment, effective treatment is a priority. The treatment of bipolar depression is quite challenging. Treatments used during acute episodes include antidepressants, some antipsychotic drugs such as quetiapine, the anticonvulsant drug lamotrigine and lithium. Response to these agents both acutely and during maintenance treatment is often partial. There are concerns about the potential for switching into mania and more frequent cycling mood with antidepressant treatment.
Only a handful of treatments are approved for bipolar depression and have been shown to be superior to placebo (lurasidone, valproate, quetiapine, the combination of fluoxetine and olanzapine, olanzapine alone, and lamotrigine), however atypical antipsychotics carry significant burden of side effects in particular metabolic.
Ketamine has been shown to be efficacious and well tolerated in MDD and BP depression, with low risk of inducing manic switch; other glutamatergic agents like memantine or lamotrigine are used as augmentation in depression and are well tolerated. Therefore, investigators believe Xenon could be well tolerated both in MDD and BP depression and possibly helpful in alleviating the symptoms.
The investigators hypothesize that patients with a primary diagnosis of depression will have a greater decrease in depressive symptoms after one session of xenon inhalation added to treatment as usual (X- TAU) compared to their session with nitrogen-oxygen inhalation added to treatment as usual (N-TAU). The investigators will specifically randomize the 20 patients to receive in random order one session of X- TAU and one session of N-TAU. Blind ratings of depression will be done with the modified Hamilton Depression Rating Scale (HDRS) and Quick Inventory of Depressive Symptomatology-Clinician Version (QIDS-C) at baseline and at predefined time intervals by clinicians experts in mood disorder who will be completely blinded to all the administration procedures.
The methods for depression assessments will be consistent with those used for the early proof-of-concept ketamine studies with assessments at 40, 80, 110, and 230 minutes post-administration and 1, 3, and 7 days post-administration. The primary outcome will be improvement at day 1. Mixed model repeated measures analysis will be used to compare the two groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants and has the potential to be a novel antidepressant drug. \- xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group)
Drug: Xenon
Nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group)
Drug: Nitrogen gas
The investigators have chosen to use as a maximum concentration about half the general anesthetic partial pressure of xenon (35%=70%/2) to achieve a dose that is sub-anesthetic. This concentration of xenon is very close to that at which subjects emerging from xenon anesthesia first respond to verbal commands, commonly referred to as MAC awake.
nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual
Depressive Symptoms
Hamilton Depression Rating Scale (HDRS):This scale is a 6-item survey which is one of the most frequently used instruments for evaluating depression in adults, the questionnaire allows clinicians to assess the nature and severity of mood disorders in patient populations. Score Range: 0-42, higher scores means worse outcomes
Time frame: Improvement at day 1
Depressive Symptoms
Quick Inventory of Depressive Symptomatology-Clinician Version (QIDS-C): The Quick Inventory of Depressive Symptomatology (QIDS) is designed to assess the severity of depressive symptoms. The questions to be administered by the clinician assess the severity of the nine diagnostic symptom criteria used in DSM. Score Range: 0-48, higher scores means worse outcomes
Time frame: Improvement at day 1
Plan to share: No
Ran from Dec 2019 to primary completion in Nov 2025, 71 months.
Of 49 non-industry phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 16. This study's 71 months is above that.
Counting every sponsor, half of 89 studies reached it within 16 months; a quarter within 5 and three quarters within 45.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Sep 2026 → Nov 2025 and completion Dec 2026 → Nov 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Xenon
Massachusetts General Hospital →